Acuta Capital Partners’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-511,500
Closed -$43.5M 60
2020
Q3
$43.5M Sell
511,500
-33,500
-6% -$1.69M 11.81% 1
2020
Q2
$19.3M Buy
+545,000
New +$15.9M 5.58% 2
2020
Q1
Sell
-150,000
Closed -$3.17M 46
2019
Q4
$3.17M Buy
+150,000
New +$2.65M 0.79% 29
2019
Q3
Sell
-225,000
Closed -$3.12M 38
2019
Q2
$3.12M Sell
225,000
-275,000
-55% -$4.14M 1.11% 24
2019
Q1
$9.61M Buy
500,000
+100,000
+25% +$1.61M 4.57% 7
2018
Q4
$5.71M Sell
400,000
-1,655,500
-81% -$32.9M 4.35% 8
2018
Q3
$42.8M Sell
2,055,500
-2,694,500
-57% -$63.8M 15.27% 1
2018
Q2
$112M Sell
4,750,000
-1,100,000
-19% -$22.1M 20.01% 1
2018
Q1
$85.5M Sell
5,850,000
-900,000
-13% -$14.7M 13.96% 1
2017
Q4
$109M Buy
6,750,000
+12,294
+0.2% +$145K 20.59% 1
2017
Q3
$94.2M Buy
6,737,706
+5,137,706
+321% +$51.2M 16.88% 1
2017
Q2
$14.1M Buy
1,600,000
+1,097,000
+218% +$7.7M 3.95% 9
2017
Q1
$3.25M Sell
503,000
-4,197,000
-89% -$21.3M 0.77% 34
2016
Q4
$17.2M Buy
4,700,000
+850,000
+22% +$2.51M 6.41% 4
2016
Q3
$12.5M Sell
3,850,000
-350,000
-8% -$979K 4.7% 4
2016
Q2
$9.74M Sell
4,200,000
-1,326,172
-24% -$4.43M 4.68% 5
2016
Q1
$13.8M Buy
5,526,172
+1,562,139
+39% +$3.51M 7.73% 3
2015
Q4
$12.2M Buy
3,964,033
+2,252,966
+132% +$6.29M 5.82% 5
2015
Q3
$2.94M Buy
+1,711,067
New +$4.37M 1.7% 23

Acuta Capital Partners's IMMU Position: Q4 2020 in Review

Acuta Capital Partners sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 511,500 shares — an estimated $43.5M sold.

Acuta Capital Partners first reported a position in IMMU in Q3 2015 and held it in 19 quarters. The position peaked at $112M in Q2 2018. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Acuta Capital Partners reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 511,500 Immunomedics Inc shares in Q4 2020, an estimated $43.5M.
  • Acuta Capital Partners first reported a position in Immunomedics Inc in Q3 2015 and held it in 19 quarters.
  • Acuta Capital Partners's Immunomedics Inc position peaked at $112M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.